Drugmakers 'outraged' at England's Cancer Drugs Fund decision to remove drugs from coverage

8 January 2015
ukparliament-big

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought in for the first time. NHS England said the current system was unsustainable and that there were new drugs "that will do more for patients."

Pharmaceutical companies say they are "outraged" at a "fundamentally flawed" decision that will damage patient care as the National Health Service will deny access to a range of expensive cancer treatments. They have threatened legal action, according to reports by the Financial Times and public broadcaster the BBC.

UK Prime Minister David Cameron set up a separate pot of money in 2010 to give patients access to expensive drugs, irrespective of cost. The £280 million ($425 million)-a-year Cancer Drugs Fund is hugely popular and has been used by about 55,000 people. But as things stand it expects to be £100 million over budget by the end of the financial year, the BBC noted. A full NHS England announcement on which drugs are being struck off the approved list is expected on Monday, but rejected drugs companies have started to break ranks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical